The Vaccine Book. New Insights, Approaches, and Technologies. Edition No. 3

Table of Contents

Part I: Vaccines status quo
1. Currently available viral vaccines, their targets and technologies
2. Currently available bacterial & parasite vaccines, their targets and technologies
3. Immunology behind mechanism of action of vaccines
4. Adjuvants and their use in vaccines
5. Vaccine discovery approaches and tools
6. Vaccine development, regulatory path and launch in the market
7. Health economics of vaccines
8. COVID-19: a disaster and a revolution

Part II: New vaccines and technologies for addressing unmet medical needs???
9. Key vaccines still lacking globally and their potential impact (including AMR)
10. New approaches and tools for discovering vaccines
11. New technologies and tools for designing vaccines
12. New vaccine platforms technologies: mRNA, DNA, viral vectors, OMV, bioconjugates.
13. Technical, manufacturing, regulatory and development aspects of mRNA-based vaccines
14. Faster ways for developing vaccines
15. Getting ready to next pandemics

Authors

Fabio Bagnoli Glaxo Smith Kline, Italy. Fabio Bagnoli is Senior Director at GSK, Research & Development. He is Discovery Project Leader & Translation Science Leader. As Discovery Project Leader he drives several teams composed of experts in all areas of research & development with the aim of discovering and developing new vaccines and monoclonal antibodies. As Translational Science Leader he is driving clinical research studies, biomarkers identification, and human organotypic modelling. Research conducted by Fabio led to the development of various vaccine candidates as well as filing of various patents and publications on different human pathogens. He has served as editor of several publications and as coordinator of industrial-academic efforts. Rino Rappuoli Glaxo Smith Kline, Italy. Rino Rappuoli?is Senior Vice President, Head of Vaccine Research and Development at GSK. Previously, he served as visiting scientist at?Rockefeller University?and?Harvard Medical School?and held roles at Sclavo, Vaccine Research and CSO, Chiron Corporation, and?Novartis?Vaccines. He is Chief Scientist and Head External R&D, GSK Vaccines and has served as visiting scientist at Rockefeller University and Harvard Medical School. He is an elected member of the US National Academy of Sciences and the European Molecular Biology Organization. His awards include the Paul Ehrlich and Ludwig Darmstaedter Prize (1991), Italian President Gold Medal (2005), Albert Sabin Gold Medal (2009). In 2013 he was nominated third most influential person worldwide in the field of vaccines (Terrapin). In 2015 he was awarded Fellowship of Imperial College Faculty of Medicine London and the Maurice Hilleman Award. Sanjay Phogat President, GSK, Research and Development, Italy. Sanjay Phogat is Vice President at GSK, Research & Development. He is the Discovery Performance Unit (DPU) head. As DPU head along with his team, he drives the discovery portfolio which includes bacterial, fungal vaccines, and monoclonal antibodies against infectious diseases. Sanjay is an infectious diseases expert with over twenty years of experience and a strong understanding of vaccine research and development. Sanjay's unique experience covers a broad range of organizations varying from academia, government, not-for-profit, and pharma. He is scientific advisor for nonprofit organizations discovering antibodies for HIV and co-founder of Global Alliance of Indian biomedical professional and NIH visiting fellow committee. He has served as editor/co-editor/reviewer of several publications and has published over 80 scientific papers; many are highly cited and in very high impact journals.